Key takeaway: IOL Chemicals and Pharmaceuticals Limited reported strong Q1 FY27 results, with revenue from operations rising 37% year-on-year to INR756 crores. EBITDA increased 60.7% to INR111 crores, and PAT grew 89.9% to INR64.5 crores. The pharmaceutical division saw non-ibuprofen products contribute 43% of revenue, up from 36% in Q1 FY26, driven by improved capacity utilization, favorable product mix, and export growth. The chemical segment also performed well, with exports reaching 28.5% of revenue. Management highlighted strategic focus on diversifying the API portfolio, expanding international regulatory approvals (e.g., NMPA for clopidogrel in China), and enhancing operational efficiency. Guidance for FY27 includes 15-20% revenue growth, 14-15% EBITDA margins, and 25-30% export contribution. Capex plans include INR200-250 crores annually, with 60% allocated to expansion and new products. The company emphasized sustainable growth through integrated manufacturing, backward integration, and R&D initiatives, though specific details on new projects or regulatory approvals were not provided. Management noted that while ibuprofen remains a key product, the non-ibuprofen portfolio is expected to reach 50% contribution in the near term.

Key takeaway: The investor presentation for IOL Chemicals and Pharmaceuticals Limited for Q1 FY27 reported a revenue from operations of ₹756.3 crore, reflecting a year-on-year increase of 37.1%. The presentation highlighted a profit after tax (PAT) of ₹64.5 crore, which represented an 89.9% increase compared to the same quarter last year. EBITDA for the quarter was reported at ₹111.7 crore, with an EBITDA margin of 14.6%. The document detailed the company's strategic focus on expanding its non-Ibuprofen product portfolio, which has grown from 18% to 37% in the pharmaceuticals segment over the past six years. Additionally, the company announced plans for future expansion, including the acquisition of 101 acres of land for new site development. Management set a revenue growth goal of 15%-20% for FY26-27, with an EBITDA margin guidance of 14%-15%.

Key takeaway: The earnings conference call for IOL Chemicals and Pharmaceuticals Limited on May 22, 2026, highlighted a strong financial performance for Q4 FY26, with revenue from operations reaching INR 619 crores, a 17.4% increase year-on-year. The full year revenue stood at INR 2,319 crores, reflecting an 11.5% growth. Management reported a significant improvement in EBITDA, which rose by nearly 40% to INR 94 crores for the quarter, and a 29% increase for the full year. Profit after tax for Q4 was INR 53 crores, up 68% from the previous year. The company emphasized its focus on operational efficiencies and capacity utilization, particularly in its non-Ibuprofen API segment. Management also discussed ongoing investments in capacity expansion and infrastructure, with a planned capex of INR 200-250 crores annually. The call concluded with management expressing confidence in sustaining growth momentum and improving profitability.

Key takeaway: The investor presentation for IOL Chemicals and Pharmaceuticals Limited for Q4 FY26 reported a revenue from operations of ₹619.5 crore, reflecting a year-on-year increase of 17.4%. The profit after tax (PAT) for the quarter was ₹53.2 crore, up 68.2% from the previous year, with a PAT margin of 8.6%. For the full fiscal year, the company achieved a revenue of ₹2,319.1 crore, a growth of 11.5%, and a PAT of ₹137.7 crore, representing a 36.4% increase. The presentation highlighted a strategic focus on expanding the non-Ibuprofen segment, which has grown from 18% to 37% of the pharmaceuticals segment over six years. Additionally, the company has acquired land for future expansion and is pursuing regulatory approvals for its products. The document also emphasized the company's commitment to sustainability and ESG initiatives.

Key takeaway: On February 12, 2026, IOL Chemicals and Pharmaceuticals Limited held its earnings conference call to discuss financial results for Q3 and the nine months ended December 31, 2025. Management reported a resilient quarter, highlighting the strength of its diversified business model despite global challenges. The pharmaceutical segment was noted as a key growth driver, particularly in non-ibuprofen APIs, which contributed to improved revenue visibility and margin quality. Revenue from operations for Q3 was INR 580 crores, a 10.9% increase year-on-year, with EBITDA rising 22.8% to INR 62.6 crores. The company declared an interim dividend of 50% per equity share, reflecting confidence in its performance. Management emphasized ongoing efforts to expand in regulated markets and enhance R&D capabilities. The call concluded with management expressing optimism about sustaining performance momentum and delivering long-term value for stakeholders.

Key takeaway: The investor presentation for IOL Chemicals and Pharmaceuticals Limited reported the financial results for Q3 and the nine-month period ending December 31, 2025. For Q3 FY26, the company achieved revenue from operations of ₹580.4 crore, a 10.9% increase year-over-year, with a profit before tax (PBT) of ₹38.8 crore, reflecting a 39.3% year-over-year growth. The EBITDA for the quarter was ₹62.6 crore, marking a 22.8% increase. For the nine-month period, revenue reached ₹1,699.6 crore, up 9.6% year-over-year, with a PBT of ₹124.8 crore, a 34.2% increase. The presentation highlighted the company's strategic focus on expanding its non-Ibuprofen API segment and its commitment to backward integration for supply chain resilience. Additionally, the company reported plans for future expansion, including land acquisition for new site development. The document also detailed the company's certifications and commitment to sustainability initiatives.